Skip to main content

Advertisement

Table 1 Criteria for dose suspension or reduction

From: Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study

Toxicity Grade Resumption plan
Neutrophil count (with preventive treatment by G-CSFa) Grade 4 (lasting for 5 days or more) Preventive treatment by G-CSF.
Neutrophil count (without preventive treatment by G-CSF) Grade 4 (lasting for 5 days or more) Reduced dose of 720 mg/m2 of GEMa and 55mg/m2 of DTXa (first occurrence), then 570 mg/m2 of GEM and 44mg/m2 of DTX (second occurrence).
Diarrhea Grade 3
Mucositis oral Grade 3
Infection Grade 3
Pneumonitis Grade 1
Grade 2 Discontinue protocol treatment.
Neuropathy Grade 2 Reduced dose of 720 mg/m2 of GEM and 55mg/m2 of DTX (first occurrence), then 570 mg/m2 of GEM and 44mg/m2 of DTX (second occurrence).
Grade 3 Discontinue protocol treatment.
Creatinine Grade 2-4
Supraventricular tachycardia Grade 2 (two times), Grade 3
Atrial arrhythmia Grade 2 (two times), Grade 3
Left ventriclar contractile dysfunction Grade 2 (two times), Grade 3
Vertigo/Dizziness Grade 2-3
Depressed level of consciousness Grade 2-3
Seizure Grade 2-3
Leukoencephalopathy Grade 2-3
Non-hematological toxicity Grade 4
Any adverse events which occurred with dose of 570 mg/m2 of GEM and 44mg/m2 of DTX.
  1. aG-CSF Granulocyte colony stimulating factor, GEM Gemcitabine, DTX Docetaxel